# reload+after+2024-01-23 00:47:51.313545
address1§9920 Pacific Heights Boulevard
address2§Suite 350
city§San Diego
state§CA
zip§92121
country§United States
phone§858 704 4660
website§https://www.vikingtherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
fullTimeEmployees§23
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Brian  Lian Ph.D.', 'age': 57, 'title': 'President, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 965115, 'exercisedValue': 0, 'unexercisedValue': 5242550}, {'maxAge': 1, 'name': 'Mr. Gregory S. Zante', 'age': 52, 'title': 'Chief Financial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 603500, 'exercisedValue': 0, 'unexercisedValue': 366013}, {'maxAge': 1, 'name': 'Ms. Marianne  Mancini', 'age': 58, 'title': 'Chief Operating Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 633300, 'exercisedValue': 0, 'unexercisedValue': 1412689}, {'maxAge': 1, 'name': 'Mr. Michael  Morneau', 'age': 58, 'title': 'Vice President of Finance & Administration', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 375333, 'exercisedValue': 0, 'unexercisedValue': 490518}, {'maxAge': 1, 'name': 'Dr. Geoffrey E. Barker Ph.D.', 'title': 'Senior Vice President of Pharmaceutical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.526
currency§USD
dateShortInterest§1702598400
forwardEps§-1.12
pegRatio§-0.5
exchange§NCM
quoteType§EQUITY
shortName§Viking Therapeutics, Inc.
longName§Viking Therapeutics, Inc.
firstTradeDateEpochUtc§1430227800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e658b393-1b8d-3e3b-b1d5-0d5bdf22cb43
gmtOffSetMilliseconds§-18000000
targetHighPrice§40.0
targetLowPrice§28.0
targetMeanPrice§34.0
targetMedianPrice§35.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§9
quickRatio§28.067
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
